drugset
drugset / Trial / NCT00162110

A Trial of Erbitux for Recurrent and Metastatic Mucinous Gastrointestinal Adenocarcinoma Involving the Peritoneal Surfaces

NCT00162110 ↗

Phase 2 Completed 40 enrolled Eli Lilly and Company
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This is a Phase II open-label trial evaluating the efficacy, and safety of Erbitux in patients with mucinous gastrointestinal adenocarcinoma involving the peritoneal surface.

Timeline

Start
2004-11
Primary completion
2007-01
Completion
2007-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Cetuximab Monoclonal antibody 225 mg/m2 —

Indications

mucinous adenocarcinoma